Biosimilars, too, are expected to gain ground as healthcare systems worldwide look for cost-effective alternatives to ...

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

Trump’s EO on MFN prescription drugs to strengthen adoption of generics & biosimilars: Nandita Vijayasimha, Bengaluru Thursday, May 15, 2025, 08:00 Hrs [IST] US President Donald ...

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

Tata Steel's revenue fell 4.2 percent to Rs 56,218.11 crore in the March quarter compared to Rs 58,687.31 crore in the ...

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely ...

Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

By linking US drug prices to those paid in similar economies, order could alter how pharmaceutical companies price their ...

Biocon and Biocon Biologics Executive Chairperson, Kiran Mazumdar-Shaw, says they're adding capacity at their insulin ...

Bengaluru: Biocon, an Indian biopharmaceutical company, has reported a more than twofold increase in its fourth-quarter ...

FY25 revenue at Rs. 4,454 crore up by 15%, net profit at Rs 344 crore: Our Bureau, Bengaluru Friday, May 9, 2025, 12:30 Hrs [IST] Biocon in its consolidated financial re ...